A2 Biotherapeutics
Agoura Hills, US · Founded 2017 · Delaware corporation · 4 known investors
A2 Biotherapeutics develops precision CAR T-cell therapies for people with cancer and other diseases using its Tmod cell engineering platform for autologous and allogeneic applications. The company advances these therapies through clinical trials.
Founders & leadership
SF
Scott ForakerExecutive Officer, Director
SA
Srini AkkarajuDirector
MB
Madhavan BalachandranDirector
MG
Michael GalloDirector
DG
David GoeddelDirector
CA
C. Alexander KambDirector
HS
Helen S. KimDirector
JL
Jakob LovenDirector
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$71.6MraisedDec 2022 · 28 investors · BiotechnologyRule 506(b)
▶$71.6MraisedDec 2022 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Madhavan BalachandranDirector
- Helen S. KimDirector
- Scott ForakerExecutive Officer, Director
- David LucasExecutive Officer
- Susan L. KelleyDirector
- Srini AkkarajuDirector
- Jakob LovenDirector
- William GoExecutive Officer
- Thomas LeungExecutive Officer
- Alexander KambExecutive Officer, Director
- David GoeddelDirector
- Offering amount
- $71.6M
- Amount sold
- $71.6M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$71.5MraisedOct 2020 · 13 investors · BiotechnologyRule 506(b)
▶$71.5MraisedOct 2020 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott ForakerExecutive Officer, Director
- Srini AkkarajuDirector
- Madhavan BalachandranDirector
- Michael GalloDirector
- David GoeddelDirector
- C. Alexander KambDirector
- Helen S. KimDirector
- Jakob LovenDirector
- Offering amount
- $71.5M
- Amount sold
- $71.5M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.